News

Cognition Therapeutics Unveils Phase 2 Study Insights on DLB

Cognition Therapeutics Unveils Phase 2 Study Insights on DLB

Cognition Therapeutics Unveils Key Insights from Phase 2 Study on DLB

- Patient characteristics are consistent with other DLB studies -

PURCHASE, N.Y. — Cognition Therapeutics, Inc. (NASDAQ: CGTX), a clinical-stage company focused on developing innovative drugs for neurodegenerative disorders, recently presented crucial findings regarding the participant demographics in their Phase 2 ‘SHIMMER’ study targeting mild-to-moderate dementia with Lewy bodies (DLB). This significant data was highlighted at the Annual Clinical Trials on Alzheimer’s Disease (CTAD) conference, taking place in Madrid.

Understanding the Participant Demographics

The study included a robust cohort of 130 participants, demonstrating mean scores indicative of mild-to-moderate cognitive impairment, key elements relevant to DLB. This suggests that the fluctuations in attention observed align with recognized clinical benchmarks for diagnosing DLB. In addition, the majority of participants exhibited mild movement impairment, further validating their condition.

As explained by Anthony Caggiano, M.D., Ph.D., Cognition’s Chief Medical Officer and Head of Research and Development, the characteristics observed in this study resonate with findings in previous research dedicated to DLB.

Detailed Overview of Baseline Characteristics

The baseline characteristics gleaned from the poster presented at CTAD were as follows:

  • Mean Age: 72.8 years
  • Gender Distribution: 81.5% male
  • Race: 91.5% white
  • Mean MMSE Score: 24.0
  • Mean MoCA Score: 18.4
  • Mean CAF Score: 5.9
  • Mean ESS Score: 8.4
  • Mean MDS-UPDRS Part III Score: 27.7
  • Mean ADCS-ADL Score: 62.5

These statistics help paint a comprehensive picture of how DLB affects participants and align closely with other studies aiming to identify effective treatment pathways.

Context on Dementia with Lewy Bodies

DLB is noted as the second most common form of dementia, impacting approximately 1.4 million individuals in the United States alone. This degenerative condition results from the pathological buildup of the protein ?-synuclein, forming aggregates known as Lewy bodies within neurons. Patients may present a range of symptoms including fluctuating consciousness, hallucinations, delusions, and movement disorders.

As Lisa Ricciardi, Cognition’s president and CEO, remarked, understanding these characteristics in relation to other studies highlights the importance of continued research in this area.

The SHIMMER Study's Approach

The SHIMMER study is a meticulously designed double-blind, placebo-controlled clinical trial involving 130 adults diagnosed with mild-to-moderate DLB. Participants are randomly administered either a placebo or one of two doses of CT1812 (100 mg or 300 mg) for a duration of six months. This study method allows for reliable assessments of cognitive performance via various established metrics such as the MoCA and MMSE.

The study is receiving significant funding support from the National Institutes of Health (NIH), specifically from the National Institute on Aging, with a grant exceeding $30 million. Collaborations are in place with some esteemed centers specializing in Lewy body dementia to ensure comprehensive data collection and participant care.

Exploring the Role of CT1812

CT1812 represents a forward-thinking approach to treatment, characterized as an experimental small molecule that carefully targets the sigma-2 receptor complex while overcoming the blood-brain barrier. Preliminary studies exhibit promising results indicating its ability to displace harmful A? oligomers, which are implicated in Alzheimer's disease and cognitive decline.

Cognition Therapeutics is actively recruiting participants for their related studies in Alzheimer’s disease and other degenerative conditions, demonstrating commitment to advancing innovative therapeutic strategies.

A Glimpse into Cognition Therapeutics

Cognition Therapeutics, Inc. is dedicated to discovering and establishing powerful new treatments aimed at age-related degenerative disorders affecting both the central nervous system and retina. The company’s innovative approach with CT1812 and their extensive pipeline for ?-2 receptor modulation highlights a unique position in the potential treatment landscape for these challenging diseases.

Frequently Asked Questions

What is the SHIMMER study about?

The SHIMMER study is a Phase 2 clinical trial aimed at evaluating the efficacy of CT1812 in participants with mild-to-moderate dementia with Lewy bodies.

How many participants are involved in the SHIMMER study?

The study includes 130 participants who are being assessed over the course of the trial.

What are some common symptoms associated with DLB?

DLB symptoms include fluctuations in attention, hallucinations, movement disorders, and changes in cognitive abilities.

What approach does CT1812 take for treatment?

CT1812 is designed as a small molecule oligomer antagonist, targeting the sigma-2 receptor to alleviate cognitive impairment caused by toxic protein aggregation.

Where can I learn more about Cognition Therapeutics?

Further information about Cognition Therapeutics, including their clinical programs, can be found on their official website.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Memorial Manor's Five-Star Signal in Long-Term Care

Updated Category News Views 130

Care quality is the only score that matters here A nursing home recognition is not the sort of news anybody should read like a trophy-case press release and then forget by lunch. Families make decisions around long-term care when they are tired, worried, and often dealing with a parent or spouse whose needs have changed fast. In that setting, a facility putting up both a...

Continue Reading
Thoughts Unleashed Arrives With a Personal American Voice

Updated Category News Views 114

A lifetime of observation finally gets its own page Forty is an unusual age to begin writing poetry, which is exactly why Joyce Ann Grooms McGeehan's debut has a little more texture than the usual polished promise of inspiration. Thoughts Unleashed by an Independent, American Woman comes from someone who spent decades teaching French, English, and ESL, then retired to a...

Continue Reading
AMPERA Joins Berto to Power Future Energy Innovations

Updated Category News Views 163

The Power Play You Didn't See Coming AMPERA and Berto just made a move that could stir up some serious waves in the energy sector. They've inked a business combination deal set to push advanced energy technology to the forefront. With AMPERA's valuation clocking in at roughly $900 million, this partnership aims to bring cutting-edge power solutions from concept to market....

Continue Reading
Alpha's Training Bet Reaches Into Aesthetic Care Networks

Updated Category News Views 186

Training is becoming part of the operating machine A certificate course is rarely the headline-grabber in healthcare services, yet this one deserves a closer look. Alpha Aesthetics Partners has launched Practice Aesthetics, a unified clinical education platform tied directly to its expanding network of medical aesthetics practices. This is not a public-market ticker...

Continue Reading
Benicia's Bold Move to Streamline Permitting Pays Off

Updated Category News Views 147

Award-Winning Innovation from Benicia Benicia, California, shoots ahead of the pack by scooping up a highly coveted Helen Putnam Award for Excellence. Why? They chopped down bureaucracy like a lumberjack with a new ax by ushering in a digital revolution for their permitting process. Make no mistake, folks, this ain’t just a pat on the back—it's a blueprint for cities...

Continue Reading
Unishippers Climbs 18 Slots on 32.4% Sales Growth Run

Updated Category News Views 127

Thirty new franchise units can move the needle fast Unishippers did not inch its way up the Franchise Times Top 400; it put up a number that deserves a hard look. Sales rose 32.4% in 2025, the company added 30 franchise units, and the result was an 18-place jump to No. 81 on the 2026 ranking. In the shipping category, it was named the sales-growth leader. For a business...

Continue Reading
New Flight Charters Puts a Cap on Winter Surprises

Updated Category News Views 151

Ice on a wing is routine; ice on an invoice is where charter customers start muttering. New Flight Charters says it will again absorb de-icing and hangar charges this winter, up to $2,500 per trip, marking the seventh consecutive season for the program. In a business where the headline quote can look tidy and the final bill can arrive wearing muddy boots, that is a...

Continue Reading
Legato Frames Put Tiny AI to a Real-World Hearing Test

Updated Category News Views 142

A hearing aid that never enters the ear is a deceptively brutal product challenge. It has to hear speech through a mess of restaurant clatter, traffic, wind and ordinary human commotion; it has to run all day; and, crucially, it cannot look like a medical concession somebody reluctantly straps on. Legato Frames are aiming right at that knot, with femtoAI providing the...

Continue Reading
Suntory Flowers Tests NASCAR as a Garden Retail Engine

Updated Category News Views 24

Orange sheet metal and flowering vines are an odd couple, which is precisely why this South Florida promotion has some bite. A plant marketer took a hard left turn Suntory Flowers put its Sun Parasol mandevillas alongside DGM Racing at Homestead-Miami Speedway, celebrating the millions of plants grown in South Florida. That is not a conventional horticulture play, and...

Continue Reading
SanMar’s Lott Tops Promo Products Power 50 Again in 2026

Updated Category News Views 102

Branded hoodies and logo tumblers rarely make Wall Street’s pulse race, but the numbers behind them deserve a hard look. Jeremy Lott, president and CEO of SanMar, was named the most influential leader in the U.S. promotional-products business for the second consecutive year, taking No. 1 in the 2026 Counselor Power 50 ranking. Awards can be fluff. A repeat win beside...

Continue Reading

Top 5 Most Recently Viewed Articles

La-Z-Boy Faces Major Stock Decline After Weak Earnings Report

Updated Category News Views 264

La-Z-Boy Stock Experiences Significant Drop La-Z-Boy Incorporated (NYSE: LZB) witnessed a dramatic 23.55% decline in after-hours trading, with shares plummeting from $39.11 to $29.90. This downturn followed the release of disappointing first-quarter results that did not meet analysts' expectations, prompting concerns about operational challenges. Disappointing Earnings...

Continue Reading
CLEAR Secure, Inc. Reveals Impressive Q3 2025 Performance

Updated Category News Views 224

CLEAR Secure, Inc.'s Q3 2025 Financial Overview CLEAR Secure, Inc. (NYSE: YOU), the leader in secure identity technologies, has recently unveiled its financial highlights for the third quarter of the 2025 fiscal year. As an innovative firm at the forefront of identity verification, CLEAR continues to address the growing needs in the security sector amid increasing cyber...

Continue Reading
Ameren Corporation Celebrates 10 Years of Disability Inclusion

Updated Category News Views 62

Ameren Corporation Champions Disability Inclusion Ameren Corporation (NYSE: AEE) has made impressive advancements in promoting disability inclusion, scoring a perfect 100 on the Disability Equality Index for the tenth year running. This recognition highlights Ameren’s role as a leader in fostering an inclusive workplace that values diversity and actively supports...

Continue Reading
Labcorp Faces Lawsuit: Wiretapping Accusations Surface

Updated Category News Views 60

Labcorp's Legal Tangle Unveiled One minute you're on Labcorp's website searching for medical info, the next you're caught up in a class-action legal whirlwind. Legal drama is not on any patient’s checklist, but here we are, with Labcorp knee-deep in some serious allegations. The crux of the matter points to alleged wiretapping violations, with claims that Labcorp,...

Continue Reading
Advent's $2.5 Billion Acquisition of Sapiens: A New Era Looms

Updated Category News Views 203

Advent to Acquire Sapiens for $2.5 Billion Sapiens International Corporation N.V. (NASDAQ: SPNS), a leader in software solutions for the insurance sector, has seen its stock price soar following the exciting announcement that it will be acquired by global private equity firm Advent. The all-cash acquisition deal is valued at approximately $2.5 billion, indicating a...

Continue Reading